<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31526" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Scleroderma and Renal Crisis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidya</surname>
            <given-names>Prabhakar N.</given-names>
          </name>
          <aff>Campbell University School of OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basyal</surname>
            <given-names>Bikash</given-names>
          </name>
          <aff>Abington Jefferson Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Finnigan</surname>
            <given-names>Nancy A.</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhakar Vaidya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bikash Basyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nancy Finnigan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31526.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Scleroderma renal crisis is a life-threatening complication of scleroderma. It typically presents with the abrupt onset of severe hypertension accompanied by rapidly progressive renal failure, hypertensive encephalopathy, congestive heart failure, and/or microangiopathic hemolytic anemia. This activity describes the evaluation, diagnosis, and management of scleroderma renal crisis and stresses the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe factors that suggest increased risk of developing scleroderma renal crisis.</p></list-item><list-item><p>Review the typical presentation of scleroderma renal crisis.</p></list-item><list-item><p>Explain the management of scleroderma renal crisis.</p></list-item><list-item><p>Identify strategies to optimize care coordination among interprofessional team members to improve outcomes for patients affected by scleroderma renal crisis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31526&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31526">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31526.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Scleroderma renal crisis is a life-threatening complication of scleroderma and presents with the abrupt onset of severe hypertension accompanied by rapidly progressive renal failure, hypertensive encephalopathy, congestive heart failure,&#x000a0;and/or microangiopathic hemolytic anemia.</p>
      </sec>
      <sec id="article-31526.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Most cases of scleroderma renal crisis occur in patients with diffuse scleroderma (10% to 25%) as compared to only 1% to 2% of patients with limited disease. The disease usually occurs early in the course of scleroderma, up to 75% of cases of scleroderma renal crisis developing within the first 4 years from the diagnosis with the median duration of scleroderma at the time of diagnosis of scleroderma renal crisis being 8 months. It may sometimes be the initial presenting feature of scleroderma (scleroderma renal crisis sans scleroderma).</p>
        <p>Factors predictive of scleroderma renal crisis include diffuse skin involvement, especially with rapid progression, the presence of anti-RNA polymerase III antibod&#x000ad;ies, corticosteroid therapy in doses greater than 15 mg a day, tendon friction rubs, new onset anemia, pericarditis, and congestive heart failure.<xref ref-type="bibr" rid="article-31526.r1">[1]</xref><xref ref-type="bibr" rid="article-31526.r2">[2]</xref><xref ref-type="bibr" rid="article-31526.r3">[3]</xref><xref ref-type="bibr" rid="article-31526.r4">[4]</xref><xref ref-type="bibr" rid="article-31526.r5">[5]</xref></p>
      </sec>
      <sec id="article-31526.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Scleroderma renal crisis was reported to occur in as many as 20% of patients with scleroderma in the older literature, but the prevalence of this disease seems to be decreasing and currently reported to occur in about 5- 10 % of patients with scleroderma. Early studies suggested that African-American patients and males were more likely to develop scleroderma renal crisis but later studies have not born this out. The prevalence rate also is different in different countries, and there is a seasonal variation in presentation with a greater number of patients presenting in winter and fall months.</p>
      </sec>
      <sec id="article-31526.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of scleroderma renal crisis is not well understood. Injury to the endothelial cells results in structural changes in the blood vessels (intimal thickening and proliferation, fibrin deposition) in the initial stages. Decreased blood flow from the structural changes in the blood vessels as well as renal vasospasm (&#x0201c;Raynaud&#x02019;s phenomenon&#x0201d;) causes renal ischemia, hyperplasia of the juxtaglomerular apparatus, activation of the renin-angiotensin-aldosterone system (RAAS), and rise in BP. The critical rise in BP causes further damage to renal blood vessels and initiates a vicious cycle eventually leading to malignant hypertension.<xref ref-type="bibr" rid="article-31526.r1">[1]</xref></p>
      </sec>
      <sec id="article-31526.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Changes are seen characteristically in small interlobular and arcuate arteries, and the predominant pathologic changes are similar to those observed in malignant hypertension and other thrombotic microangiopathies.<xref ref-type="bibr" rid="article-31526.r1">[1]</xref><xref ref-type="bibr" rid="article-31526.r2">[2]</xref><xref ref-type="bibr" rid="article-31526.r6">[6]</xref><xref ref-type="bibr" rid="article-31526.r7">[7]</xref><xref ref-type="bibr" rid="article-31526.r8">[8]</xref></p>
        <p>Myxoid intimal proliferation with luminal narrowing occurs early and as the lesions progress, smooth muscle cell infiltration and deposition of collagen occurs in the intima, resulting in the appearance of concentric fibrosis or &#x0201c;onion skin&#x0201d; appearance. Superimposed fibrin thrombi and fibrinoid necrosis of the media are also seen.<xref ref-type="bibr" rid="article-31526.r1">[1]</xref><xref ref-type="bibr" rid="article-31526.r2">[2]</xref><xref ref-type="bibr" rid="article-31526.r6">[6]</xref><xref ref-type="bibr" rid="article-31526.r7">[7]</xref></p>
        <p>Glomeruli may show ischemic collapse or fibrinoid necrosis. The tubules show changes due to ischemic injury with tubular degeneration and necrosis in acute stages. In the chronic stages, tubular atrophy and interstitial fibrosis develop and are proportional to vascular injury.<xref ref-type="bibr" rid="article-31526.r7">[7]</xref></p>
      </sec>
      <sec id="article-31526.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The typical presentation of scleroderma renal crisis is a combination of abrupt onset of severe hypertension associated with oligo-anuric acute renal failure in a patient with diffuse scleroderma. Non-nephrotic proteinuria and hematuria with benign urine sediment are common. Other clinical features include hypertensive retinopathy, encephalopathy with a headache, confusion, change in mental status and altered vision, congestive heart failure, thrombocytopenia, and microangiopathic hemolytic anemia.[<xref ref-type="bibr" rid="article-31526.r1">[1]</xref><xref ref-type="bibr" rid="article-31526.r2">[2]</xref>.</p>
      </sec>
      <sec id="article-31526.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Renal biopsy is not necessary in a classic setting but may be needed in patients with an atypical presentation, for example, a patient with scleroderma with rising serum creatinine who is normotensive or has either active urine sediment or nephrotic range proteinuria.<xref ref-type="bibr" rid="article-31526.r7">[7]</xref></p>
      </sec>
      <sec id="article-31526.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Activation of RAAS plays a crucial role in the pathogenesis of scleroderma renal crisis. Furthermore, the use of angiotensin-converting enzyme inhibitors (ACEIs) in this condition has dropped 1-year mortality to 24% from 85% before the use of these drugs. Therefore, the current practice is to lower blood pressure&#x000a0;rapidly&#x000a0;with ACEIs and maintain it.<xref ref-type="bibr" rid="article-31526.r1">[1]</xref><xref ref-type="bibr" rid="article-31526.r3">[3]</xref><xref ref-type="bibr" rid="article-31526.r9">[9]</xref></p>
        <p>Once the diagnosis of scleroderma renal crisis is made, the patient should be hospitalized, and ACEI therapy started. It is usual, to begin with, short-acting ACEI like captopril and rapidly titrate the dose to lower systolic blood pressure (BP) by about 20 mm Hg in 24 hours and reaching goal BP of 120/70 mm Hg within 72 hours while avoiding hypotension. Once BP is at goal and dose stabilized, long-acting ACEI can be substituted in equivalent doses.</p>
        <p>If BP cannot be controlled with maximum doses of ACEI, a dihydropyridine calcium channel blocker can be added. Diuretics should be avoided (unless dictated by the need to control volume status) because they may further stimulate RAAS.</p>
        <p>ACEI therapy may result in further decline in function to the point of necessity to initiate dialysis therapy. Continued therapy is recommended as approximately 50% of these patients may recover sufficient kidney function over 3 to 18 months to discontinue dialysis.</p>
        <p>Even though the use of these ACEIs has resulted in improvement in outcome of patients with scleroderma renal crisis, they do not prevent the disease and may increase the risk of death if used before the development of scleroderma renal crisis. This may be due to delay in making a diagnosis of this disease due to normalization of BP.</p>
        <p>Elevated circulating endothelin-1 have been described in scleroderma and endothelin receptor antagonists may have a role in the management of scleroderma renal crisis. A vasodilating prostaglandin (prostacyclin) may provide both rapid control of blood pressure and improved renal blood flow.</p>
        <p>Renal recovery may occur as long as 24 months after development of scleroderma renal crisis, and decisions about renal transplantation should be postponed until that time.</p>
        <p>There is significant survival benefit of successful renal transplantation compared with long-term dialysis. Renal transplant recipients, however, have lower graft survival rates compared to non-scleroderma patients and patient survival rates are lower as well, most likely due to the progression of disease in other visceral organs. Recurrence of scleroderma renal crisis in the transplanted kidney is uncommon (5%) but has been described, particularly in patients who had a&#x000a0;more aggressive disease before transplantation.<xref ref-type="bibr" rid="article-31526.r2">[2]</xref><xref ref-type="bibr" rid="article-31526.r3">[3]</xref>.</p>
      </sec>
      <sec id="article-31526.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Thrombotic microangiopathy, malignant hypertension, and rapidly progressive glomerulonephritis frequently enter into the differential diagnosis of scleroderma renal crisis.</p>
        <p>BP is markedly elevated in both malignant hypertension and scleroderma renal crisis, and it may be difficult to distinguish between the two unless there is a clear-cut history of antecedent poorly controlled hypertension.</p>
        <p>In rapidly progressive glomerulonephritis, blood pressure is mildly elevated, urine sediment is nephritic, and there is a greater degree of proteinuria compared to scleroderma renal crisis. In cases that are not clear, serological testing for various causes of rapidly progressive glomerulonephritis would be indicated.</p>
        <p>In patients who develop scleroderma renal crisis as the initial manifestation of scleroderma, renal biopsy may be the only way to clinch the diagnosis.</p>
      </sec>
      <sec id="article-31526.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>ACEIs have changed the outcome of patients with scleroderma renal crisis. Before the use of these drugs, a 1-year survival rate of patients with this disease did not exceed 10%; whereas, patients treated with ACE inhibitors now can anticipate 85% survival at 1 year and 65% survival at 5 years.<xref ref-type="bibr" rid="article-31526.r10">[10]</xref></p>
        <p>Up to two-thirds of patients with scleroderma renal crisis may require renal replacement therapy. Half of these patients will eventually recover sufficient renal function to discontinue dialysis. Dialysis status affects the mortality rate in scleroderma renal crisis, mortality being greater in dialyzed patients versus those who do not need dialysis, and being lesser in those whose renal function improved and were able to come off dialysis versus those who needed to continue dialysis. Risk factors for poor outcome in scleroderma renal crisis include the following<xref ref-type="bibr" rid="article-31526.r1">[1]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum creatinine greater than 3 mg/dl at presentation</p>
          </list-item>
          <list-item>
            <p>Delay in initiating antihypertensive treatment</p>
          </list-item>
          <list-item>
            <p>Inadequate BP control</p>
          </list-item>
          <list-item>
            <p>Older age</p>
          </list-item>
          <list-item>
            <p>Male gender</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Scleroderma renal crisis occurring without hypertension</p>
          </list-item>
          <list-item>
            <p>Renal biopsy findings showing arteriolar fibrinoid necrosis, severe glomerular ischemic collapse or severe tubular atrophy and interstitial fibrosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31526.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Scleroderma renal crisis presents with the abrupt onset of severe hypertension accompanied by rapidly progressive renal failure, hypertensive encephalopathy, congestive heart failure,&#x000a0;and/or microangiopathic hemolytic anemia. RAAS activation plays a crucial role in the pathogenesis of scleroderma renal crisis, and use of angiotensin-converting enzyme inhibitors (ACEIs) 1-year mortality which was 85% before the use of these drugs has dropped to 24% with the use of these drugs. Therefore, the current practice is to lower blood pressure rapidly with ACEIs and maintain it.</p>
      </sec>
      <sec id="article-31526.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Scleroderma renal crisis is a serious complication of scleroderma and requires close coordination of care between patient's primary care physician, rheumatologist and nephrologist. Early diagnosis and prompt initiation of treatment with ACEis is essential for better outcomes and despite transient worsening of renal function and rise of serum creatinine, continued therapy with ACEI is warranted and may potentially lead to eventual recovery of renal function.&#x000a0;<xref ref-type="bibr" rid="article-31526.r9">[9]</xref><xref ref-type="bibr" rid="article-31526.r10">[10]</xref></p>
      </sec>
      <sec id="article-31526.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31526&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31526">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/scleroderma-and-renal-crisis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31526">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31526/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31526">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31526.s15">
        <title>References</title>
        <ref id="article-31526.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Kidney involvement in systemic sclerosis.</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10 Pt 2</issue>
            <fpage>e305</fpage>
            <page-range>e305-14</page-range>
            <pub-id pub-id-type="pmid">25174767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bose</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chiesa-Vottero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma renal crisis.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>687</fpage>
            <page-range>687-94</page-range>
            <pub-id pub-id-type="pmid">25613774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghossein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fenves</surname>
                <given-names>AZ</given-names>
              </name>
            </person-group>
            <article-title>Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">26711696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma renal crisis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>549</fpage>
            <page-range>549-54</page-range>
            <pub-id pub-id-type="pmid">26352732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodworth</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Suliman</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma renal crisis and renal involvement in systemic sclerosis.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>678</fpage>
            <page-range>678-691</page-range>
            <pub-id pub-id-type="pmid">27641135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Domsic</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Medsger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bastacky</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma renal crisis: a pathology perspective.</article-title>
            <source>Int J Rheumatol</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>543704</fpage>
            <pub-id pub-id-type="pmid">20981312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma Renal Crisis.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-88</page-range>
            <pub-id pub-id-type="pmid">26210130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lusco</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Najafian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>AJKD Atlas of Renal Pathology: Systemic Sclerosis.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>e19</fpage>
            <page-range>e19-20</page-range>
            <pub-id pub-id-type="pmid">27012948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanatta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Polito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Favaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapy of scleroderma renal crisis: State of the art.</article-title>
            <source>Autoimmun Rev</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>882</fpage>
            <page-range>882-889</page-range>
            <pub-id pub-id-type="pmid">30005860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31526.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Howie</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kingdon</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bunn</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma renal crisis: patient characteristics and long-term outcomes.</article-title>
            <source>QJM</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>100</volume>
            <issue>8</issue>
            <fpage>485</fpage>
            <page-range>485-94</page-range>
            <pub-id pub-id-type="pmid">17601770</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
